|
gptkbp:instanceOf
|
clinical trial
|
|
gptkbp:approves
|
institutional review board
|
|
gptkbp:careInstructions
|
obinutuzumab plus chemotherapy
rituximab plus chemotherapy
|
|
gptkbp:clinicalTrials
|
ClinicalTrials.gov
|
|
gptkbp:collaborations
|
gptkb:European_Organization_for_Research_and_Treatment_of_Cancer
gptkb:National_Cancer_Institute
|
|
gptkbp:collection
|
clinical assessments
|
|
gptkbp:completed
|
2019
|
|
gptkbp:complications
|
infections
infusion reactions
neutropenia
|
|
gptkbp:criteria
|
adult patients
previous anti-CD20 therapy
|
|
gptkbp:dataTransmission
|
available upon request
|
|
gptkbp:diseaseResistance
|
NCCN_guidelines
|
|
gptkbp:dosageForm
|
chemotherapy
|
|
gptkbp:duration
|
at least 2 years
|
|
gptkbp:encouraged
|
obtained from all participants
|
|
gptkbp:enrollment
|
diverse population
|
|
gptkbp:foundedIn
|
2014
|
|
gptkbp:funding
|
pharmaceutical industry
|
|
gptkbp:future_plans
|
III
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
GALLIUM trial
|
|
gptkbp:internationalRelations
|
multiple countries
|
|
gptkbp:is_studied_in
|
sample size
generalizability
randomized controlled trial
multicenter study
|
|
gptkbp:outcome
|
quality of life
time to progression
symptom burden
|
|
gptkbp:participants
|
approximately 1400
|
|
gptkbp:performedBy
|
gptkb:Roche
|
|
gptkbp:primaryMission
|
progression-free survival
|
|
gptkbp:publishes
|
gptkb:The_New_England_Journal_of_Medicine
2020
|
|
gptkbp:recognizes
|
NCT01332968
|
|
gptkbp:regulatoryCompliance
|
FDA_approval
EMA_approval
|
|
gptkbp:relatedTo
|
rituximab
obinutuzumab
|
|
gptkbp:research
|
follicular lymphoma
|
|
gptkbp:secondary_mission
|
gptkb:Dr._John_Smith
|
|
gptkbp:secondaryMission
|
overall survival
|
|
gptkbp:significance
|
p<0.05
|
|
gptkbp:sponsor
|
gptkb:Genentech
|
|
gptkbp:technique
|
intention-to-treat
1:1 ratio
|
|
gptkbp:technology
|
long-term outcomes
explore combination therapies
biomarker_identification
|
|
gptkbp:yearsActive
|
ongoing
|